A healthcare professional at Seattle Plastic Surgery can provide specific guidelines tailored to our unique needs
By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake [3] [10]
Thus, previous studies on this topic are still scarce, treatments and study populations vary, and findings have been mixed
While some observational data and post-hoc analyses of clinical trials have reported reductions in serum uric acid among patients treated with GLP-1 agonists, these findings have not been consistently replicated across all studies
Reflecting a growing acceptance of obesity as a legitimate medical condition, at least in the United State, a 2024 employer health benefits survey found that 61% of respondents support expanding Medicare (federal health insurance program primarily for individuals aged 65 and older) coverage beyond treatment for T2DM to include GLP-1 therapies for weight management in overweight individuals (Kaiser Family, F, 2024)
"With the surge in GLP-1 medication use for weight loss, we recognized a critical gap in the market for tailored nutritional support," said Muriel Gonzalez, President of The Vitamin Shoppe
